Company intelligence / Profile preview
Fractal Tun
Cambridge, Massachusetts, United Statesfractaltx.com ↗
- Ownership
- Private
- Employees
- ~20
- Development stage
- Other
01
Overview
Fractal Therapeutics is a biotechnology company focused on developing next-generation therapies for metabolic diseases, specifically targeting the root causes of type 2 diabetes and obesity. The company utilizes a systems biology approach and advanced computational modeling to design interventions that aim to provide long-term disease remission rather than just symptom management. Their lead programs focus on optimizing GLP-1 and GIP signaling pathways through novel delivery and molecular mechanisms. Fractal's strategy involves leveraging a deep understanding of metabolic feedback loops to create more durable and effective treatments.
- Therapeutic areas
- Endocrinology
- Modalities
- Small moleculeGene therapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Fractal Tun.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fractal Tun.